Condensed Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2025	Mar. 31, 2024
Operating expenses:
Research and development	$ 30,637	$ 30,503
General and administrative	11,508	10,303
Restructuring, impairment, and costs of suspended programs	46,280
Total operating expenses	88,425	40,806
Loss from operations	(88,425)	(40,806)
Interest income	3,938	5,005
Other expense, net	(11)	(10)
Net loss	(84,498)	(35,811)
Other comprehensive loss:
Unrealized loss on marketable securities	(195)	(279)
Comprehensive loss	$ (84,693)	$ (36,090)
Net loss per share attributable to common stockholders, basic	$ (1.77)	$ (0.87)
Net loss per share attributable to common stockholders, diluted	$ (1.77)	$ (0.87)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic	47,852,079	40,995,901
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted	47,852,079	40,995,901